Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Number of employees : 262 people.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
DNA Immunotherapies and Vaccines4.11100%7.41100% +80.24%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States4.11100%7.41100% +80.24%
Managers
NameAgeSinceTitle
J. Joseph Kim, Dr.512009President, Chief Executive Officer & Director
Peter D. Kies562002Chief Financial Officer
Laurent M. Humeau, Dr.532019Chief Scientific Officer
Kate E. Broderick, Dr.-2007Senior Vice President-Research & Development
Mammen P. Mammen, Dr.562020Senior Vice President-Clinical Development
Stephen Kemmerrer-2007Senior Vice President-Engineering Development
Jacqueline E. Shea, Dr.542019Chief Operating Officer & Executive Vice President
Simon X. Benito752019Chairman
Wendy L. Yarno652017Independent Director
Lota S. Zoth602019Independent Director
Members of the board
NameAgeSinceTitle
Simon X. Benito752019Chairman
J. Joseph Kim, Dr.512009President, Chief Executive Officer & Director
David B. Weiner, Dr.642016Director
Wendy L. Yarno652017Independent Director
Lota S. Zoth602019Independent Director
Ann Calby Miller, Dr.632019Independent Director
Jay P. Shepard612020Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 208,306,017 200,489,971 96.2% 0 0.0% 96.2%
Stock B 0 1,091 0 0.0% 1,082 99.2%
Shareholders
NameEquities%
SSgA Funds Management, Inc. 8,894,555 4.27%
The Vanguard Group, Inc. 8,684,511 4.17%
Nikko Asset Management Co., Ltd. 5,156,350 2.48%
BlackRock Fund Advisors 4,501,585 2.16%
Wasatch Advisors, Inc. 3,939,018 1.89%
Coatue Management LLC 3,576,923 1.72%
VHCP Management LLC 2,900,000 1.39%
Geode Capital Management LLC 2,524,403 1.21%
J. Joseph Kim 2,152,031 1.03%
Northern Trust Investments, Inc.(Investment Management) 1,903,696 0.91%
Holdings
NameEquities%Valuation
GeneOne Life Science, Inc. (A011000) 1,799,8584.02%18,606,878 USD
Company contact information
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462-1111

Phone : +1.267.440.4200
Fax : +1.267.440.4242
Web : http://www.inovio.com
Sector Other Biotechnology & Medical Research